A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients


Kayaaslan B., Akinci E., Ari A., KOÇAK TUFAN Z., NAYMAN ALPAT S., Gunal O., ...More

CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.42, no.1, pp.40-47, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 42 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.1016/j.clinre.2017.06.008
  • Journal Name: CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.40-47
  • Keywords: Entecavir versus Tenofovir, Chronic Hepatitis B (CHB), Hepatitis B Virus (HBV), Efficacy, Predictors of response, DISOPROXIL FUMARATE, CLINICAL-PRACTICE, EFFICACY, THERAPY
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Background: Entecavir (ETV) and tenofovir disoproxil fumarat (TDF) are the two first-line therapies recommended in the treatment of chronic hepatitis B because of having potent antiviral effect and high genetic barriers against resistance. We aimed to compare efficacy of these drugs and to evaluate predictors of viral suppression.